This article provides an update on our prior analysis of the infliximab litigation involving Janssen Biotech, Inc. (“Janssen”),...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]
BPCIA
-
-
Introduction The Amgen, Inc. and Amgen Manufacturing, Limited (“Amgen”) litigation against Hospira, Inc. (“Hospira”), filed in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Pfizer announced last week that the FDA’s Oncologic Drug Advisory Committee (ODAC) recommended its proposed biosimilar to Amgen’s...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Earlier this month, Janssen Biotech, Inc., a subsidiary of Johnson and Johnson, (“Janssen” or “Plaintiff”) filed a Complaint in...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Partner Nikki Gifford gave a presentation entitled “Intellectual Property – Recent Developments and Implications,” at the World...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Introduction and Background The Apotex filgrastim/pegfilgrastim biosimilar litigation was the first biosimilar litigation where the...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
The Supreme Court heard oral arguments on Wednesday in its first biosimilar case. On a petition filed in Sandoz, Inc. v. Amgen, Inc., et...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Genentech filed suit against Amgen this past February when a dispute arose between the parties during the first step of the “patent...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK] -
Editors’ Note: Although the BPCIA was enacted seven years ago, to date, only four biosimilar products have been approved by the FDA, and...
http://twitter.com/share?text="[TITLE]&url=[PERMALINK]